Belgium-based eTheRNA NV has changed its business strategy in order to exploit the potential of its technology platform to provide services to the RNA therapeutics industry. Previously, the company’s focus was on proprietary messenger RNA (mRNA) drug development. But with the support of a new €39 million financing round, the company has changed its model to focus on services.
